TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Exhaled Breath Condensate pH in Patients With Cough Caused by Gastroesophageal Reflux

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* age \> 18 years old~* able to speak and read English~* chronic cough~Exclusion Criteria:~* Cigarette smoking within the past 6 months, or greater than 10 pack year history of prior smoking~* Any self-reported or clinically diagnosed form of active lung disease, including asthma and emphysema~* Symptoms of persistent rhinitis within the past three months~* Dysphagia~* Symptoms of acute viral upper respiratory tract infection or sinusitis within one month of entry into the study~* Pregnancy - based on self report~* Abnormal chest radiograph

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: None): Chronic cough caused by GERD
- 2 (Type: None): Chronic cough without GERD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Bone Strength Measured by DensiProbe on Bone Related Fixation Failure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients 50 years or older~* Patients with trochanteric or femoral neck fractures, classified as: AO 31-A1, AO 31-A2, AO 31-A3, AO 31-B1, AO 31-B2, AO 31-B3~* Patients undergoing fixation with DHS (135° aiming device, anti-rotational K-wire)~* Patients willing to participate in the study according to the clinical investigation plan~* Patients able to understand and read country national language at an elementary level~* Signed written informed consent by the patient or legal guardian~Exclusion Criteria:~* Bilateral hip fractures (at present or in the past)~* Open hip fracture~* Any previous surgical procedures of the hip (ipsilateral / contralateral)~* More than 7 days between injury and surgery~* Polytrauma (multiple injuries, whereof one or the combination of several injuries is life-threatening)~* Patients being pregnant or breast-feeding~* Pathologic fractures~* Active malignancy~* Psychiatric disorders that would preclude reliable assessment (e.g. severe depression)~* Drug or alcohol abuse~* Patients having participated in any other device or drug related clinical trial within the previous month

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Relationship Between Gut Microbiome and Adjuvant Chemotherapy in Patients With Early Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically diagnosed stage I-III breast cancer;~* Plan to receive adjuvant chemotherapy in our hospital;~* Sign the informed consent;~* Good compliance and willing to follow up.~Exclusion Criteria:~* Those who have started receiving adjuvant chemotherapy;~* Chemotherapy contraindications;

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Function, Endothelin, and Inflammation in Pre-diabetic Obesity Versus Lean Healthy Controls

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* healthy~* normotensive (BP\<140/95 mmHg)~* lean and obese~* 18 and 55 years~* women must be premenopausal~Exclusion Criteria:~* use of pharmacologic agents or recreational drugs, with the exception of occasional use of non-narcotic pain medications~* blood pressure (\>140/90 mmHg)~* elevated cholesterol (LDL \>130 mg/dL)~* diabetes mellitus (by ADA criteria)~* evidence of coronary and/or peripheral vascular disease by history and physical exam~* \>5 kg change in weight in the preceding 3 months~* chronic systemic illness with recognized metabolic effects~* hepatitis C and HIV~* recognized systemic inflammatory or autoimmune processes such as rheumatoid arthritis or systemic lupus erythematosis~* Raynaud's phenomenon or other abnormalities of hand or finger perfusion~* regular participation in endurance or high-performance athletic activity~* history of aspirin or salsalate sensitivity including aspirin-induced asthma~* prior treatment with salsalate, pentoxyfilline, or monoclonal anti-TNFalpha antibodies~* pregnancy~* liver transaminase levels \>3 times the upper limit of normal~* creatinine \>1.5 mg/dL~* history of a cellular immunodeficiency-related opportunistic infections, such as an endemic mycosis (eg. histoplasmosis) or mycobacterial infection (eg tuberculosis)~* reactive tuberculin skin test~* history of malignancy except for basal cell carcinoma of the skin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Acute Salsalate (Type: EXPERIMENTAL): Nondiabetic lean and obese subjects will be studied in this arm. Subjects will be studied at baseline and after a single dose of oral salsalate.
- Chronic Salsalate - Obese (Type: EXPERIMENTAL): Obese subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate.
- Chronic Salsalate - Lean (Type: EXPERIMENTAL): Lean subjects will be studied in this arm. Subjects will be studied at baseline and after 2 months' treatment with oral salsalate. The effects of an acute fatty acid infusion on vascular function will be measured on both occasions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TENS Trial to Prevent Neuropathic Pain in SCI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18;~* Traumatic spinal cord injury;~* Date of injury occurring within four months of study enrollment.~Exclusion Criteria:~* More than four months since date of injury;~* Contraindications for the study intervention, transcutaneous electrical nerve stimulation (TENS),88 including:~* Implanted electronic device such as a pacemaker;~* Cardiovascular problems;~* Pregnancy;~* Epilepsy;~* Cancer;~* Persons with a spinal cord injury at the C2 level, as placement of TENS electrodes on the neck is not recommended;~* Cognitive dysfunction which limits the ability of the participant to adequately understand procedures and risks.~* Prisoners~* Pregnant Women~Special populations:~* Adults unable to consent: excluded from study~* Individuals -who are not yet adults: individuals who are less than 18 years old will be excluded from the study~* Pregnant women: Women who are known to be pregnant will not be recruited into the study. A pregnancy test will be administered to females prior to enrollment in TENS (or sham) treatment. Women who become pregnant before or during the 8-week TENS treatment period will be discontinued from the study. Women who become pregnant after the 8-week TENS treatment portion of the study will continue to be enrolled, and followed according to protocol guidelines (no information will be collected specifically on the pregnancy or fetus).~* Prisoners: excluded from study~* Neonates: not applicable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active TENS (Type: EXPERIMENTAL): Participants are given 30 minutes of TENS therapy twice a week for 8 weeks.
- Sham TENS (Type: SHAM_COMPARATOR): Electrodes are placed on participants for 30 minutes twice a week for 8 weeks without TENS stimulation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Trial of Chromium-Metformin Combination in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~ICD-9 Diagnosis of TYpe 2 Diabetes (250.XX) for two years or less and treated with metformin Patients having completed dose titration of metformin as prescribed by their physician and have reached a stble dose between 1000-2550 mg per day for at least two months HbA1c: 7.0-10.5%~Exclusion Criteria:~* Duration of metformin treatment longer than 1 year at start time of study medication Historical or current use of oral anti-diabetes (OAD) medication (other than metformin) or use of insulin History ofmyocardial infarction within the lat 6 months, unstable angina, uncontrollable hypertension with systolic greater than 180 or diastolic greater than 110.~Clinical or objective finding suggestive of congestive heart failure. Individuals not receiving routine management by their primary car eproviders and/or endocrinologists for their type 2 diabetes, including routine ECG and ophthamological evaluations.~Women of child-bearing age not using standard birth control measures. Hemoglobin \<11 or \> 16; Hematocrig \<32 or \> 50; WBC \<3,000 or \>12,000; Platelets \<150,000 or \>500,000 Serum Creatinine \>1.4 mg/dL; BUN \>25 mg/dL Presence of greater than +1 protein on random macroscopic urinalysis at screening without a rule out of microalbuminuria Total bilirubin \>1.5 mg/dL LFTs: AST\>60 IU/L; ALT\>65/L; Alkaline phosphatase \>120 Iu/L. Isolated LFT elevations with an ultrasound diagnosis of non-alcoholic Steatohepatitis and a lab rule out of viral hepatitis will be included in the study with careful monitoring of LFTs.~Subjects currently taking nutritional supplements, including multivatmin for study duration; subjects will be asked to discontinue any nutritional supplementation at the screening telephone interview 1 week prior to screening lab work and 4 week sprior to baseline lab work.~Subjects taking lipid lowering medications except statins (i.e. niacin, fibrates, resins) due to possible chromium binding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Loop Drainage: Effectiveness in Treating Cutaneous Abscesses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years or older~2. Presents to ED with simple cutaneous abscess~3. Provides informed consent.~Exclusion Criteria:~1. Under 18 years of age~2. Abscess too small for performance of procedure~3. Signs of systemic infection~4. Need for hospitalization~5. Previously treated for current abscess~6. Clinician determines abscess would not be amenable to drainage by loop technique~7. Patients known to be pregnant~8. Incarcerated patients~9. Students / Employees of the facility~10. Presence of any other condition(s) that the investigator feels makes the patient unsuitable for study inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Traditional Incision and Drainage (Type: ACTIVE_COMPARATOR): Treatment of a simple cutaneous abscess with traditional incision and drainage with or without packing, decision made at the discretion of the provider.
- Loop drainage (Type: EXPERIMENTAL): Treatment of a simple cutaneous abscess with incision and drainage using the loop drainage technique.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Subjects with type 2 diabetes mellitus~* On a stable regimen of metformin alone, metformin and a DPP4, metformin and a TZD, or metformin, a DPP4, and a TZD for a minimum of 3 months prior to randomization~* Body mass indices \> 25 and \< 45 kg/m2~* Hemoglobin A1c levels ≥ 7.0% and ≤ 11.0% at screening~* Fasting C-peptide levels ≥ 0.2 nmol/L at screening~* Subject with a history of hypertension must be on a stable antihypertensive treatment (s) (type of medication, dose, and regimen) for at least 6 weeks prior to the first dose of investigational product~* Other criteria may apply~Exclusion Criteria~* Subject has type 1 diabetes mellitus or history of type 1 diabetes mellitus~* Subject has had 2 or more emergency room visits or hospitalizations due to poor glucose control in the 6 months prior to screening~* Poorly controlled hypertension defined as diastolic pressure ≥ 95 mmHg or systolic ≥ 155 mmHg (confirmed by a repeat assessment) at screening~* Triglycerides ≥ 400 mg/dL (4.52 mmol/L) at screening~* Use of any known cytochrome P450 (CYP) inducers within 30 days or 5 half-lives (whichever is longer), prior to receiving the first dose of investigational product.~* Use of any known inhibitors of CYP3A4/P-glycoprotein within the 14 days or 5 half lives (whichever is longer) prior to receiving the first dose of investigational product~* Other criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AMG 151 (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* New York Heart Association (NYHA) class II-III heart failure~* receiving optimal medical therapy~* sedentary~Exclusion Criteria:~* smoking~* changes in medication or major cardiovascular (CV) event or procedure within the previous 6 wk~* fixed rate pacemaker~* unstable angina~* other co-morbidities or limitations that preclude safe participation in the exercise testing~* plans for hospitalization or cardiac transplantation within the next 2 months~* type 1 diabetes~* refusal or inability to provide informed consent

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo drink, single dose, taste and color-matched to experimental drink
- beet juice concentrate (Type: EXPERIMENTAL): single dose of beet juice concentrate, roughly 70 mL

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proximal TEmporary oCclusion Using Balloon Guide Catheter for Mechanical Thrombectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥18 years~2. Diagnosis of AIS with confirmed anterior circulation LVO (including intracranial segment of the internal carotid artery, and the first or proximal second segment \[M1 or proximal M2\] of the middle cerebral artery) by brain imaging~3. To receive MT within 24 hours after AIS onset according to local guidelines~4. Preoperative mRS score of 0-1~5. Signed informed consent form obtained from the subject (or approved surrogate)~Exclusion Criteria:~1. Intracranial hemorrhage confirmed by imaging~2. Known or suspected pre-existing (chronic) large vessel occlusion in the symptomatic territory~3. Excessive vascular access tortuosity disables the use of balloon guide catheter~4. Intracranial stent implanted in the same vascular territory that precludes the safe deployment/removal of the neuro-thrombectomy device~5. Any other condition that precludes the performing of mechanical thrombectomy procedure~6. Occlusions in multiple vascular territories confirmed by Computed Tomography Angiography(CTA) or Magnetic Resonance Angiography(MRA)~7. Subjects who are pregnant~8. Subjects who are allergy to the contrast agent~9. Subjects who refuse to cooperate or unable to tolerate interventional operation~10. Subjects whose expected lifetime are less than 90 days~11. Subjects who are unlikely to participate in follow-up assessments according to the investigator's judgement~12. Any other condition that, according to the investigator's judgement, not suitable for using of balloon guide catheter

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): Balloon guide catheters (BGCs)
- Control group (Type: ACTIVE_COMPARATOR): Standard guide catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of PGT-A Versus PGT-A+ERA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Majority of age patients whose written informed consent approved by the Ethics Committee (EC) has been obtained, after having been duly informed of the nature of the study and voluntarily accepted to participate after being fully aware of the potential risks, benefits and any discomfort involved.~* Patients who already have frozen euploid blastocysts (day 5/6 development) analysed by PGT-A.~* Patients with embryos obtained from their own oocytes fertilized by Intracytoplasmic Sperm Injection (ICSI) or In vitro fertilization (IVF).~* Patients with an expected embryo transfer of one or two embryos (Single ET or Double ET) in a HRT cycle.~* Body Mass Index: 18,5-30 Kg/m2.~Exclusion Criteria:~* Presence of pathologies or malformations that affect the uterine cavity such as polyps, intramural myomas ≥ 4cm or submucosal, septum or hydrosalpinx during the patient's participation in the study. Patients suffering these pathologies before or after their inclusion in the study are allowed to participate if the pathology is corrected before performing any study procedure.~* Any illness or medical condition that is unstable or which, according to medical criteria, may put at risk the patient's safety and her compliance in the study.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PGT-A without ERA (Type: OTHER): Patients with PGT-A indication and ET in a Hormone Replacement Therapy (HRT cycle) according to the usual clinical practice (day 5 of progesterone supplementation: P+5/120h).
- PGT-A and test ERA (Type: OTHER): Patients with PGT-A indication and pET in HRT cycle following the ERA test indication (when the WOI is confirmed as Receptive).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Perception of Children and Youth Receiving Non-sedated Botulinum Toxin-A Injections Using the Buzzy®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Any child and youth who receives non-sedated Botulinum toxin-A injections and is interested and consenting to using the Buzzy~Exclusion Criteria:~* Patients receiving Botulinum Toxin-A injections under sedation~* Patients younger than 2 years or older than 18 years.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Buzzy (Type: EXPERIMENTAL): Participants will use the Buzzy, a small vibration device during their Botulinum toxin treatments. The Buzzy will be held over the injection site for 30 sec prior to the injection, then will be moved more rostral during the actual injection. The Buzzy will be applied in the same fashion to each targeted muscle.
- control - no Buzzy (Type: NO_INTERVENTION): Participants in the control group will receive their regular Botulinum toxin treatment without the use of the Buzzy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval